Asian Penny Stocks: Design Capital And 2 Other Promising Picks

Simply Wall St · 1d ago

As the Asian markets navigate through a period of economic fluctuations, investors are keeping a close eye on opportunities that align with evolving market dynamics. Penny stocks, while often considered niche investments, continue to offer intriguing possibilities for growth, especially when they exhibit strong financial health. This article will explore several such stocks in the Asian market that combine affordability with potential resilience and opportunity.

Top 10 Penny Stocks In Asia

Name Share Price Market Cap Rewards & Risks
Oiltek International (SGX:HQU) SGD0.675 SGD289.57M ✅ 4 ⚠️ 2 View Analysis >
JBM (Healthcare) (SEHK:2161) HK$2.70 HK$2.21B ✅ 3 ⚠️ 1 View Analysis >
Lever Style (SEHK:1346) HK$1.47 HK$909.23M ✅ 4 ⚠️ 1 View Analysis >
TK Group (Holdings) (SEHK:2283) HK$2.56 HK$2.12B ✅ 4 ⚠️ 1 View Analysis >
CNMC Goldmine Holdings (Catalist:5TP) SGD1.02 SGD413.39M ✅ 4 ⚠️ 1 View Analysis >
Atlantic Navigation Holdings (Singapore) (Catalist:5UL) SGD0.104 SGD54.45M ✅ 2 ⚠️ 4 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.39 SGD13.34B ✅ 5 ⚠️ 1 View Analysis >
F & J Prince Holdings (PSE:FJP) ₱2.21 ₱843.44M ✅ 2 ⚠️ 3 View Analysis >
Livestock Improvement (NZSE:LIC) NZ$1.00 NZ$142.34M ✅ 2 ⚠️ 5 View Analysis >
Scott Technology (NZSE:SCT) NZ$3.12 NZ$258.17M ✅ 4 ⚠️ 1 View Analysis >

Click here to see the full list of 963 stocks from our Asian Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Design Capital (SEHK:1545)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Design Capital Limited, with a market cap of HK$248 million, operates in the furniture business across Singapore, the United States, and Malaysia.

Operations: The company's revenue is derived from Furniture Sales amounting to SGD 15 million, Interior Design contributing SGD 6.20 million, and U.S. Furniture Sales totaling SGD 32.47 million.

Market Cap: HK$248M

Design Capital Limited, with a market cap of HK$248 million, operates in the furniture sector across multiple regions. Despite being unprofitable and experiencing increased losses over the past five years, the company maintains a strong balance sheet with short-term assets exceeding both short and long-term liabilities. Its debt is well-covered by operating cash flow, and it has significantly reduced its debt-to-equity ratio over time. The recent appointment of Mr. Dillon Kho as a non-executive director may bring fresh perspectives to strategic planning. However, the share price remains highly volatile compared to other Hong Kong stocks.

SEHK:1545 Debt to Equity History and Analysis as at Dec 2025
SEHK:1545 Debt to Equity History and Analysis as at Dec 2025

Uju Holding (SEHK:1948)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Uju Holding Limited is an investment holding company that offers digital marketing services and live-streaming e-commerce in the People’s Republic of China, with a market cap of HK$2.45 billion.

Operations: The company generated CN¥10.30 billion from its All-In-One Online Marketing Solutions Services segment.

Market Cap: HK$2.45B

Uju Holding Limited, with a market cap of HK$2.45 billion, has shown resilience in the digital marketing sector in China. The company reported significant gross billing growth of RMB 11.86 billion for the first nine months of 2025, driven by strengthened customer relationships and expanded media channels. Despite past earnings volatility and a low return on equity at 7.7%, Uju's debt is well-managed with more cash than total debt and strong interest coverage by EBIT (17.7x). Recent board changes may impact strategic direction as Mr. Peng Liang resigned to focus on other commitments, signaling potential shifts in leadership dynamics.

SEHK:1948 Debt to Equity History and Analysis as at Dec 2025
SEHK:1948 Debt to Equity History and Analysis as at Dec 2025

Antengene (SEHK:6996)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on developing novel oncology therapies in Greater China and internationally, with a market cap of HK$3.04 billion.

Operations: The company generated CN¥84.35 million from its research, development, and commercialization of pharmaceutical products segment.

Market Cap: HK$3.04B

Antengene Corporation Limited, with a market cap of HK$3.04 billion, is navigating the biopharmaceutical landscape by focusing on innovative oncology therapies. Despite being unprofitable and having a negative return on equity of -29.83%, the company has not diluted shareholders over the past year and maintains a sufficient cash runway for more than two years under current conditions. Recent developments include approvals in Hong Kong for XPOVIO® combinations targeting multiple myeloma and lymphoma, as well as progress in clinical trials like CLINCH-2 evaluating ATG-022 with promising early results, indicating potential expansion into broader therapeutic areas beyond gastric cancer.

SEHK:6996 Debt to Equity History and Analysis as at Dec 2025
SEHK:6996 Debt to Equity History and Analysis as at Dec 2025

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.